Insulet (PODD)
(Delayed Data from NSDQ)
$236.58 USD
-1.10 (-0.46%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $236.69 +0.11 (0.05%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Brokerage Reports
Insulet Corporation [PODD]
Reports for Purchase
Showing records 281 - 300 ( 346 total )
Company: Insulet Corporation
Industry: Medical - Products
Q4 results inline, 2013 OmniPod guidance midpoint ahead of expectations
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: Insulet Corporation
Industry: Medical - Products
Insulin Pump Project: Historical survey of 2,900+ pump users
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: Insulet Corporation
Industry: Medical - Products
Integrated pump-CGM combo on horizon? New opportunities in 2013 and beyond
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: Insulet Corporation
Industry: Medical - Products
Company: Insulet Corporation
Industry: Medical - Products
Groundwork in place for Gen2, Q3 inline, cash operating profit, no FDA approval yet
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: Insulet Corporation
Industry: Medical - Products
Feltl Insulin Pump Project: Historical survey of 2,700+ pump users
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: Insulet Corporation
Industry: Medical - Products
Presents another hell week for medical device analysts.
Provider: CAPSTONE INVESTMENTS
Analyst: PUTNAM J
Company: Insulet Corporation
Industry: Medical - Products
Company: Insulet Corporation
Industry: Medical - Products
GAUGES IMPACT OF OBAMACARE TAX ON MEDICAL DEVICES COS.
Provider: CAPSTONE INVESTMENTS
Analyst: PUTNAM J
Company: Insulet Corporation
Industry: Medical - Products
PODD Q2 2012: slight miss, FDA clarity gained, raising PT to $24.00
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: Insulet Corporation
Industry: Medical - Products
BUY- FDA GEN2 PUMP APPROVAL DELAYED - Q2 REVS. VERY STRONG
Provider: CAPSTONE INVESTMENTS
Analyst: PUTNAM J
Company: Insulet Corporation
Industry: Medical - Products
PODD Feltl Insulin Pump Project: Historical survey of 2,500+ pump users (2007 present)
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: Insulet Corporation
Industry: Medical - Products
Termination of Coverage
Provider: RODMAN & RENSHAW, CO.
Company: Insulet Corporation
Industry: Medical - Products
Company: Insulet Corporation
Industry: Medical - Products
Medical Devices: Pending Legislation Will Increase FDA''s Reach Offset By Some Benefits
Provider: CAPSTONE INVESTMENTS
Analyst: PUTNAM J
Company: Insulet Corporation
Industry: Medical - Products
In-line quarter...All eyes on regulatory clearance of next-gen Omnipod...
Provider: RODMAN & RENSHAW, CO.
Analyst: KALIA S
Company: Insulet Corporation
Industry: Medical - Products
In-line quarter... All eyes on regulatory clearance of next-gen Omnipod...
Provider: RODMAN & RENSHAW, CO.
Analyst: KALIA S
Company: Insulet Corporation
Industry: Medical - Products
PODD Q1 2012 sales inline; not skittish on next generation OmniPod approval
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: Insulet Corporation
Industry: Medical - Products
Company: Insulet Corporation
Industry: Medical - Products
PODD Feltl Insulin Pump Project: Historical survey of 2,300+ pump users (2007 present)
Provider: FELTL & COMPANY
Analyst: HAYNOR B